Ariad Pharmaceuticals Downgraded by Stifel Nicolaus to “Hold” (ARIA)
Ariad Pharmaceuticals (NASDAQ:ARIA) was downgraded by research analysts at Stifel Nicolaus to a “hold” rating in a report released on Wednesday, American Banking News.com reports.
ARIA has been the subject of a number of other recent research reports. Analysts at JMP Securities cut their price target on shares of Ariad Pharmaceuticals to $30.00 in a research note to investors on Monday, September 30th. They now have a “market outperform” rating on the stock. Separately, analysts at Brean Capital cut their price target on shares of Ariad Pharmaceuticals from $28.00 to $26.00 in a research note to investors on Monday, September 30th. They now have a “buy” rating on the stock. Finally, analysts at Maxim Group cut their price target on shares of Ariad Pharmaceuticals from $26.00 to $24.00 in a research note to investors on Monday, September 30th. They now have a “buy” rating on the stock. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $26.25.
Ariad Pharmaceuticals (NASDAQ:ARIA) traded down 68.49% on Wednesday, hitting $5.40. 85,249,024 shares of the company’s stock traded hands. Ariad Pharmaceuticals has a one year low of $15.35 and a one year high of $25.40. The stock has a 50-day moving average of $19.47 and a 200-day moving average of $18.5. The company’s market cap is $999.6 million.
Ariad Pharmaceuticals (NASDAQ:ARIA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter last year, the company posted ($0.31) earnings per share. Ariad Pharmaceuticals’s revenue was up 4302.5% compared to the same quarter last year. On average, analysts predict that Ariad Pharmaceuticals will post $-1.63 earnings per share for the current fiscal year.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.